ScoreWhy is Concord Biotech Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate -0.48% of over the last 5 years
2
Negative results in Sep 25
- PBT LESS OI(Q) At Rs 72.33 cr has Fallen at -32.1% (vs previous 4Q average)
- PAT(Q) At Rs 63.58 cr has Fallen at -28.6% (vs previous 4Q average)
- OPERATING CF(Y) Lowest at Rs 244.52 Cr
3
With ROE of 17.7, it has a Very Expensive valuation with a 8 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -35.20%, its profits have fallen by -1.2%
4
Below par performance in long term as well as near term
- Along with generating -35.20% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Concord Biotech for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Concord Biotech
-34.17%
-0.80
43.99%
Sensex
-4.95%
0.44
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.33%
EBIT Growth (5y)
0.42%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.64
Tax Ratio
24.78%
Dividend Payout Ratio
24.63%
Pledged Shares
0
Institutional Holding
17.02%
ROCE (avg)
27.54%
ROE (avg)
17.91%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
53
Industry P/E
34
Price to Book Value
6.96
EV to EBIT
46.52
EV to EBITDA
37.09
EV to Capital Employed
8.50
EV to Sales
12.92
PEG Ratio
NA
Dividend Yield
0.80%
ROCE (Latest)
18.27%
ROE (Latest)
13.06%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-4What is not working for the Company
PAT(Latest six months)
At Rs 155.69 cr has Grown at -28.02%
Loading Valuation Snapshot...
Here's what is not working for Concord Biotech
Profit After Tax (PAT) - Latest six months
At Rs 155.69 cr has Grown at -28.02%
Year on Year (YoY)MOJO Watch
Near term PAT trend is negative
PAT (Rs Cr)
Non Operating Income - Quarterly
Highest at Rs 15.35 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
